Ytracis

RSS

yttrium [90Y] chloride

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Ytracis has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 19/01/2022

Authorisation details

Product details
Name
Ytracis
Agency product number
EMEA/H/C/000460
Active substance
yttrium (90Y) chloride
International non-proprietary name (INN) or common name
yttrium [90Y] chloride
Therapeutic area (MeSH)
Radionuclide Imaging
Anatomical therapeutic chemical (ATC) code
V09
Publication details
Marketing-authorisation holder
CIS bio international
Revision
7
Date of issue of marketing authorisation valid throughout the European Union
24/03/2003
Contact address

Route Nationale 306, Saclay
B.P. 32
F-91192 Gif sur Yvette Cedex
France

Product information

29/05/2015 Ytracis - EMEA/H/C/000460 - IAIN/0016

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Diagnostic radiopharmaceuticals

Therapeutic indication

To be used only for the radiolabelling of carrier molecules which have been specifically developed and authorised for radiolabelling with this radionuclide.
Radiopharmaceutical precursor - Not intended for direct application to patients.

Assessment history

How useful was this page?

Add your rating